VCs continue to shun the field of supercomputing despite new commercial upside related to the rise of artificial intelligence. Asia, however, could offer a relatively competitive launchpad for start-ups in the segment
The emergence of domestically-developed tech business models in China that can be exported overseas has VC investors hoping the country can become known as an innovator rather than a copycat
Teams spinning out from US endowments are competing in an increasingly competitive market for outsourced investment mandates from institutions. Scale and differentiation are the key selling points
A long-smoldering trade dispute between the US and China has begun to reverberate globally across a range of sectors. Private equity must not ignore the potential impacts
Singapore’s EDBI has joined a $42 million funding round for Puppet, a US-based creator of software development and operation tools, with the goal of driving expansion in Asia.
World Innovation Lab (WiL) has raised $521 million for a US-Japan venture capital fund.
A global commercial property services provider that TPG Capital and PAG Asia Capital created through the merger of Australia’s DTZ with US-based Cassidy Turley and Cushman & Wakefield, has filed for a US IPO.
The Blackstone Group has achieved a final close on its maiden Asia-focused private equity fund at a revised hard cap of $2.3 billion.
Pivotal BioVenture Partners China, an investment platform of Hong Kong conglomerate Nan Fung Group, has led a $16.5 million seed round for Sino-US cancer drug developer Oncologie.
Cornerstone Capital, a China-based PE firm that focuses on pre-IPO investments, has filed for an IPO on NASDAQ.
Chinese automotive industry supplier Weifu High Technology Group has led a $40 million Series E round for Protean Electric, a US and China-based auto equipment developer backed by a number of VC investors.
California Public Employees’ Retirement System's (CalPERS) decision to launch a private equity direct investment strategy sets it apart from its counterparts, but the plan will need conviction and focus to succeed
Ally Bridge Group, Hillhouse Capital and 6 Dimensions Capital have co-led a $300 million Series C round for Grail, a biotechnology development firm based in Hong Kong and the US.
Hong Kong has altered its IPO regime to attract tech companies with unorthodox shareholding structures and biotech start-ups with no revenue. But only certain businesses are welcome to apply
Permira and Hillhouse Capital will sell their stakes in Magento Commerce, a US company that provides transaction-processing software to e-commerce players, to Adobe as part of a $1.7 billion transaction.
Apax Partners has sold its remaining 48% interest in GlobalLogic, an IT outsourcing company founded by several Indian entrepreneurs, to Partners Group. The deal values the business at more than $2 billion.
California Public Employees’ Retirement System (CalPERS), the largest public pension fund in the US, plans to deploy up to $13 billion a year in direct private equity deals through two newly formed funds.
Canada Pension Plan Investment Board (CPPIB) continues to ramp up its exposure to Asian private equity, with called and uncalled commitments rising 27% to C$17.1 billion ($13.3 billion) for the 12 months ended March 2018.
Next 10 Ventures, a US and Singapore-based GP headed by former YouTube and Warner Bros executives, has raised $50 million for a fund focused on user-generated media content businesses.
KPCB has led a $20 million Series B funding round for BorderX Lab, a US-based e-commerce services company that helps global retailers connect with Chinese consumers.
Start-ups looking to go public must have solid plans for long-term growth and clear targets by which their progress can be measured, according to Adena Friedman, president and CEO of NASDAQ.
Aslan Pharmaceutical, a Singapore-based drug developer that focuses on cancer treatments, has raised $42.2 million in its US IPO. The VC-backed company listed on the Taiwan Stock Exchange last June.
Qiming Venture Partners and Ruijan Capital have contributed RMB80 million ($12.6 million) to a Series B round for Wuxi Vision Pro, a Chinese ophthalmic medical device maker with operations in the US.
GGV Capital has raised RMB1.5 billion ($236 million) for its debut renminbi-denominated fund. The successful close takes the Sino-US venture capital firm’s total assets under management past $4 billion.